TIMP-2, Human, Recombinant, CHC Cells

M. W.: 24000

Recombinant, human TIMP-2 expressed in CHC cells. Migrates as a 24 kDa protein under reducing conditions on SDS-PAGE. The activation and activity of matrix metalloproteinases (MMPs) are regulated by a family of endogenous inhibitors, tissue inhibitors of metalloproteinase (TIMP). TIMP-2 is a ~21 kDa (nonreduced) or a ~24 kDa (reduced) protein on SDS-PAGE that is expressed by a variety of cell types. It forms a non-covalent, stoichiometric complex with both latent and active MMPs. TIMP-2 preferentially binds and inhibits MMP-2. TIMPs are capable of altering the metastatic potential of cancer cells and have been shown to inhibit invasion and metastasis in animal models. Useful for SDS-PAGE/immunoblot standard and inhibition studies.

Cell permeable: no

IC₅₀ against native human MMP-1 is in the range of 2-10 nM

Primary Target
Human MMP-1

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 2-10 nM against human MMP-1

Please refer to vial label for lot-specific concentration.

Lyophilized from PBS, 100 µg BSA.

Following reconstitution, aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions.

Reconstitute by adding 200 µl PBS to the tube and mixing gently until in solution.

Clermont, A., et al. 2004. Biochem. J.382, 315.
Boone, T.C., et al. 1990. Proc. Natl. Acad. Sci. USA87, 2800.
Liotta, L.A. and Stetler-Stevenson, W.G. 1990. In Seminars in Cancer Biology. Vol. 1(2), 99.
Kodama, S., et al. 1987. Collagen Rel. Res.7, 341.
Docherty, A.J.P., et al. 1985. Nature318, 66.

Sold under license of U.S. Patents 5,595,885 and 5,698,671. Manufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)